Depixus, will be participating in BSI 2023 from 13 to 17 November, 2023, Marseilles, France.
- 3-5 Impasse Reille 75014 Paris France
- info@depixus.com
Depixus, will be participating in BSI 2023 from 13 to 17 November, 2023, Marseilles, France.
Dr Adeline Feri (Principal Scientist, Product Development) and Dr Nigel Skinner (Head of Marketing) will be presenting a poster entitled ‘Single molecule real-time analysis of dynamic nucleic acid interactions’.
The Integrative Structural Biology (BSI) congress is jointly organized by the French Association of Crystallography AFC (AFC) and the French Society of Biophysics SFB (SFB). BSI 2023 is the third edition of this congress with the objective of strengthening links between the Structural Biology and Biophysics communities. This event reflects local, regional and national expertise in developmental biology, oncology, chemistry of life, glycobiology, immunology, microbiology, neuroscience, virology, as well as complementary cutting-edge biophysical analytical approaches.
Dr Christine Blancher (Head of Applications & Collaborations) and Dr Nigel Skinner (Head of Product Management & Marketing) of Depixus participated in ELRIG Drug Discovery 2023 from 18 to 19 October, 2023, Liverpool, UK.
This year’s conference tracks covered a wide range of themes including ‘omics, personalized medicine and chemistry, all focused on bringing new therapies from the lab to the patient.
Depixus presented a poster entitled ‘Single molecule real-time analysis of dynamic nucleic acid interactions’.
Depixus participated in the 20th Anniversary of the Discovery on Target Conference from 25 to 28 September, 2023, Boston, USA.
Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules.
Dr Gordon Hamilton, President and CEO, talked about how Depixus is accelerating the discovery of such novel therapeutics using its powerful new MAGNA™ technology. Don’t miss his presentation, in a talk entitled ‘Magnetic force spectroscopy – a novel approach to Improve the hit-to-lead and lead optimization phases of RNA-targeted small-molecule drug discovery’.
Dr Steve Allen (Chief Business Officer) and Dr Jimmy Ouellet (Chief Scientist) of Depixus participated in the Hanson Wade Assay Development & Screening Summit from 23 to 24 August, 2023, Boston, USA.
The inaugural RNA Assay Development & Screening Summit is the only industry-focused RNA assay discovery networking and discussion forum, dedicated to addressing and overcoming challenges drug developers face when developing RNA assays and screening tools, for efficient drug discovery.
Dr Jimmy Ouellet, Chief Scientist, talked about how Depixus is addressing the biggest bottleneck in the screening of lead compounds using its powerful new MAGNA™ technology.
Gordon Hamilton MD, CEO, participated in the RNA Leaders Europe Congress in Basel, 15 – 16 March, presenting a poster entitled ‘MAGNA™: single molecule real-time analysis of dynamic nucleic acid interactions’. We discuss how our state-of-the-art technology platform, MAGNA™ can be used to study complex biomolecular interactions between nucleic acids and small molecules, a topic that is gathering significant excitement in the pharmaceutical industry.
MAGNA™ can be used to study complex biomolecular interactions between nucleic acids and small molecules, a topic that is gathering significant excitement in the pharmaceutical industry.